Table 4.

Drug-pathway association in the DTPN of basal BC subtype

Drug	Pathway	NE	nNE and PCI (vs NE = 0.3445)
Fluorouracil	Aryl hydrocarbon receptor signaling (1); salvage pathways of pyrimidine deoxyribonucleotides (2)	0.3445	(1) 0.3241 (PCI 5.9%) (2) 0.3425 (PCI 0.56%) (1–2) 0.3208 (PCI 6.86%)
Capecitabine	Triacylglycerol degradation	0.3445	0.3429 (PCI 0.46%)
Fulvestrant	Aryl hydrocarbon receptor signaling	0.3445	0.3241 (PCI 5.9%)
Methotrexate	Salvage pathways of pyrimidine deoxyribonucleotides	0.3445	0.3425 (PCI 0.56%)
Raloxifene	Aryl hydrocarbon receptor signaling	0.3445	0.3241 (PCI 5.9%)
Tamoxifene	Aryl hydrocarbon receptor signaling	0.3445	0.3241 (PCI 5.9%)